- Cybin Inc. secures a new U.S. patent for its CYB004 program aimed at treating generalized anxiety disorder.
- The patent extends exclusivity for CYB004, a novel formulation of deuterated DMT, until 2040.
- Dosing for the Phase 2 study of CYB004 is underway, with completion expected by mid-2025.
Cybin Inc. (CYBN, Financial), a clinical-stage company focused on breakthroughs in neuropsychiatry, has announced the acquisition of a new U.S. patent for its CYB004 program, which is in Phase 2 development for treating generalized anxiety disorder (GAD). The patent, U.S. patent 12,318,477, covers innovative formulations of N,N-dimethyltryptamine (DMT) and its deuterated isotopologues designed for intramuscular injection. This addition to Cybin’s intellectual property portfolio is expected to ensure exclusivity until 2040.
Doug Drysdale, CEO of Cybin, expressed the importance of this patent as a vital asset in protecting their lead product candidates. The CYB004 program is designed to deliver short-duration, rapid-acting treatment options for anxiety disorders, incorporating patient-friendly intramuscular dosing methods. As part of their comprehensive trial plan, dosing in the Phase 2 study for CYB004 has commenced, with an anticipated completion by mid-year 2025.
Cybin boasts a robust intellectual property portfolio, with over 90 granted patents and more than 230 pending applications. The company continues to advance its mission to revolutionize mental healthcare through innovative treatment options, including the development of programs such as CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder.
